The FDA has pointed to real problems with compounded GLP-1s: dosing errors from patients measuring their own doses out of multi-dose vials (some serious enough to require hospital care), counterfeit or mislabeled products sold online, and products that arrived warm or were stored incorrectly
Clinical trial data shows substantial AHI reductions and improved blood oxygen saturation, with apnea improvements correlating strongly with the degree of weight loss (ref)
Metabolic Enhancement Metabolic Enhancement Tirzepatide, in particular, with its dual mechanism targeting both GLP-1 and GIP receptors, may offer additional metabolic benefits that complement the hormonal changes occurring during perimenopause
Sources: HMA survey KFF Employer Benefit survey CVS earnings call transcript Medicare GLP-1 Bridge Business Group on Health survey Repost to share GLP-1 coverage expansion data Follow me for more on pharmacy benefits trends (Bryce Platt, PharmD) Coverage is expanding, but this feels less like a yes/no decision and more like a shift toward tighter control
Does the color of tirzepatide affect how well it works
